This invention relates to a product that is formulated with the goal of protecting the human body from the harmful effects of ionizing and non-ionizing electromagnetic radiations. Examples of ionizing radiations addressed by this invention include, but are not limited to, gamma- and X-rays. Non-ionizing electromagnetic radiations include, but are not limited to, radio waves such as those used for mobile telecommunication comprising the fifth generation technology standard for cellular networks, also known as 5G.

This invention is based on biological quantum entanglement occurring at the level of DNA repair genes of commensal microorganisms (cyanobacteria) that are extremely resistant to the killing effects of electromagnetic radiations. The DNA repair genes that are described in this invention are those involved with the repair of DNA lesions observed as consequence of exposure to ionizing and non-ionizing radiations. Expression of these genes in cyanobacteria is induced by their culture in a medium of carbonated mineral water naturally containing the radioactive isotopes .sup.228U and its product of decay, .sup.226Ra. Superluminal particles emitted by these isotopes are the source of Cherenkov radiation that, in turn, stimulates photosynthesis in the cyanobacteria. Photosynthesis is a phenomenon based on quantum entanglement; simultaneous induction of DNA repair genes and photosynthesis, enables entanglement between the DNA repair genes of cyanobacteria and those of commensal microorganisms that are part of the human microbiota and are cultured, under the form of a proprietary probiotic blend described in detail in this document, together with cyanobacteria in the culture medium. The culture medium, in addition to naturally radioactive water, is formulated to enhance horizontal gene transfer thanks to the presence of silica from Equisetum arvense. Radio-resistant edible cyanobacteria (that are classified as prebiotics), and entangled probiotic microorganisms are encapsulated for human consumption after a conventional process of freeze-drying. Transfer of resistance to the harmful effects of electromagnetic radiations to human cells is achieved through a Lactococcus phage-encoded protein, ORF252, that is the evolutionary precursor of human proteins involved in DNA repair and cancer protection. An application of this invention consists in its use for protecting normal (healthy) human cells subjected to radiation therapy, at the same time maximizing the therapeutic effects on radiation therapy. This document also comprises the original manufacturing methods of the pre-probiotic formula briefly described above.

This invention relates to a product that is formulated with the goal of protecting the human body from the harmful effects of ionizing and non-ionizing electromagnetic radiations. Examples of ionizing radiations addressed by this invention include, but are not limited to, gamma- and X-rays. Non-ionizing electromagnetic radiations include, but are not limited to, radio waves such as those used for mobile telecommunication comprising the fifth generation technology standard for cellular networks, also known as 5G.

This invention is based on biological quantum entanglement occurring at the level of DNA repair genes of commensal microorganisms (cyanobacteria) that are extremely resistant to the killing effects of electromagnetic radiations. The DNA repair genes that are described in this invention are those involved with the repair of DNA lesions observed as consequence of exposure to ionizing and non-ionizing radiations. Expression of these genes in cyanobacteria is induced by their culture in a medium of carbonated mineral water naturally containing the radioactive isotopes .sup.228U and its product of decay, .sup.226Ra. Superluminal particles emitted by these isotopes are the source of Cherenkov radiation that, in turn, stimulates photosynthesis in the cyanobacteria. Photosynthesis is a phenomenon based on quantum entanglement; simultaneous induction of DNA repair genes and photosynthesis, enables entanglement between the DNA repair genes of cyanobacteria and those of commensal microorganisms that are part of the human microbiota and are cultured, under the form of a proprietary probiotic blend described in detail in this document, together with cyanobacteria in the culture medium. The culture medium, in addition to naturally radioactive water, is formulated to enhance horizontal gene transfer thanks to the presence of silica from Equisetum arvense. Radio-resistant edible cyanobacteria (that are classified as prebiotics), and entangled probiotic microorganisms are encapsulated for human consumption after a conventional process of freeze-drying. Transfer of resistance to the harmful effects of electromagnetic radiations to human cells is achieved through a Lactococcus phage-encoded protein, ORF252, that is the evolutionary precursor of human proteins involved in DNA repair and cancer protection. An application of this invention consists in its use for protecting normal (healthy) human cells subjected to radiation therapy, at the same time maximizing the therapeutic effects on radiation therapy. This document also comprises the original manufacturing methods of the pre-probiotic formula briefly described above.

The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder and in particular, provides honey bees with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.

The present invention relates to a composition for inhibiting the toxicity with respect to nanoparticles and particulate matters generated from the environment. Since it has been confirmed that a decrease in intracellular ATP, a decrease in cell viability, inflammation-induced morphological changes in cells and cell activation, which are induced by nanoparticles or environmentally-derived particulate matters, are inhibited by means of the composition of the present invention, the composition may be utilized as a reducing substance for the toxicity of nanoparticles and particulate matters.

A compound having formula (I) or (II) for use inhibiting Bax mediated cell death and/or apoptosis.

##STR00001##

Disclosed are compositions engineered nanovesicles and compositions comprising CD38 inhibitors and methods of using said nanovesicles and compositions to treat an inflammatory liver disease as well as in inhibiting, reducing, or repairing tissue damage to a donor organ or tissue during a transplantation procedure. In one aspect, also disclosed are method of preparing a donor organ or tissue for transplant comprising contacting the organ or tissue with the engineered nanovesicle or compositions disclosed herein.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.

The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine (example 49). (Formula (II):

##STR00001##

The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f] [1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f] [1,3]diazepine (example 49). (Formula (II)).

##STR00001##